Enzymotec (Enzymotec) Gross-Profit-to-Asset % : 25.07% (As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Enzymotec's annualized Gross Profit for the quarter that ended in Sep. 2017 was $38.02 Mil. Enzymotec's average Total Assets over the quarter that ended in Sep. 2017 was $151.68 Mil. Therefore, Enzymotec's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2017 was 25.07%.

Enzymotec Gross-Profit-to-Asset % Historical Data

The historical data trend for Enzymotec's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Gross-Profit-to-Asset % Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

37.38

35.09

20.96

21.42

20.27

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															19.67	13.07	22.84	17.68	25.07

Competitive Comparison of Enzymotec's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Enzymotec's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzymotec's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzymotec's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Enzymotec's Gross-Profit-to-Asset % falls into.

Enzymotec Gross-Profit-to-Asset % Calculation

Enzymotec's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2016 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2016 )	/	( (Total Assets (A: Dec. 2015 )	+	Total Assets (A: Dec. 2016 ))	/ count )
	=	29.987	/	( (148.926	+	146.949)	/ 2 )
	=	29.987	/	147.9375
	=	20.27 %

Enzymotec's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2017 )	/	( (Total Assets (Q: Jun. 2017 )	+	Total Assets (Q: Sep. 2017 ))	/ count )
	=	38.024	/	( (147.808	+	155.542)	/ 2 )
	=	38.024	/	151.675
	=	25.07 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2017) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Enzymotec Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Enzymotec's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016